Xiatong Biotech completed tens of millions of RMB angel round financing, and Danlu Capital exclusively invested

According to news from the investment community (ID: pedaily2012) on December 8, recently, Suzhou Xiatong Biology completed tens of millions of yuan in angel round financing , which was exclusively invested by Danlu Capital . Xiatong Bio is a biotechnology company dedicated to the research and development of characteristic nervous system-related stem cell drugs, especially in the field of oligodendrocytes and neurons. The company was jointly initiated by Dr. Guo Ying and Professor Deng Wenbin, and has complete independent intellectual property rights. It is the first cell therapy company in China dedicated to using induced pluripotent stem cell technology to treat demyelinating diseases . The company landed in BioBay, Suzhou, and entered the national-level maker space in July, the biological incubator Baituo Maker.

Nerve demyelinating diseases are a group of diseases mainly characterized by the destruction, disintegration and loss of myelin in the nervous system, including spinal cord injury, multiple sclerosis, Guillain-Barré syndrome, neuromyelitis optica, etc. The affected patients in my country up to tens of millions. Myelin sheath is a layer of membrane wrapped around the axons of nerve cells. The main physiological functions of myelin sheath are: to facilitate the rapid conduction of nerve impulses; to insulate nerve axons; to protect nerve axons. Neurons, oligodendrocytes, and microglia all play important roles in neurodemyelinating diseases. Traditional small molecule, antibody drugs have little effect on nerve demyelination-related diseases.

Induced pluripotent stem cells (iPSCs) are a type of cell obtained by reprogramming somatic cells. They have the totipotency similar to embryonic stem cells, and there is no moral and ethical controversy. The sources are widely available and versatile, avoiding the Immune rejection provides new hope for the entire field of neurobiology and clinical regenerative medicine.

The founder and CEO of the company, Ying Guo , Ph.D. from the University of Barcelona, ​​postdoctoral fellow at UC Davis, has been engaged in the research of drugs and stem cell therapy for nerve demyelinating diseases for 11 years, and is currently starting a full-time business, leading the company to establish a neural stem and glial cell differentiation platform and clinical transformation application. The co-founder, Professor Deng Wenbin, Dean of Shenzhen School of Pharmacy, Sun Yat-sen University , is one of the pioneers in the world in the application of research on cell therapy for demyelinating diseases. As early as 2011, Professor Deng’s team published the first article on the successful induction of human glial cells, and continued to publish a series of demyelinating diseases in Nature Communications, Nature Protocols, Cell Reports, Cell Stem Cell, PNAS, EMBO, etc. Mechanism and cell and drug therapy articles, and the authorization of relevant international patents.

Dr. Guo Ying said: “I am very grateful to Danlu Capital for its recognition and support of Xia Tong Bio. The clinical application of induced pluripotent stem cells is to use the differentiation potential of stem cells to induce healthy stem cells through reprogramming technology to induce treatment needs for different diseases. It is a safe, efficient and cutting-edge treatment method that provides the possibility for the treatment of many diseases. Although there are various challenges in the application of clinical-grade induced pluripotent stem cells, our company adheres to the principle of “general medical treatment” To create safe and effective treatment methods for patients with neurological diseases, improve the quality of life of patients, make unremitting efforts to innovate, and strive to transform stem cells into a conventional treatment method, and make contributions to human beings out of pain. Xia Tong The vision of Biology is to advance the R&D and production of clinical-grade stem cells as soon as possible and accelerate clinical application, so as to benefit patients with nerve demyelinating diseases around the world as soon as possible.”

Li Jie, partner of Danlu Capital Biomedicine : “iPSC technology provides great possibilities for some diseases for which existing therapies are helpless, such as neurodegenerative diseases; With years of research accumulation and profound insights, it is the only iPSC cell therapy company in China that focuses on nerve demyelinating diseases, and we look forward to the early launch of Xiatong Biotech’s products to benefit patients.”